TABLE 1.
Characteristics of included studies.
| Study | Treatment | Control | Duration (weeks) | Outcomes | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Drug | Dose* (mg/d) | Sample size (female/male) | Age* | Drug | Dose* (mg/d) | Sample size (female/male) | Age* | |||
| Hudson et al. (1998) | fluvoxamine | 260 | 42 (39/3) | 41.2 | placebo | 43 | 43 (38/5) | 43 | 9 | b |
| McElroy et al. (2000) | sertraline | 187 | 18 (16/2) | 43.1 | placebo | — | 16 (16/0) | 41 | 6 | ab |
| Ricca et al. (2001) | fluoxetine | 60 | 21 (12/9) | 25.1 | fluvoxamine | 300 | 22 (13/9) | 26.1 | 24 | b |
| Arnold et al. (2002) | fluoxetine | 71.3 | 30 (28/2) | 41.9 | placebo | 67.3 | 30 (28/2) | 40.8 | 6 | abcd |
| Pearlstein et al. (2003) | fluvoxamine | 239 | 9 | — | placebo | 264 | 11 | — | 12 | bc |
| Grilo et al. (2005) | fluoxetine | 60 | 27 (19/8) | 44.3 | placebo | — | 27 (23/4) | 43.6 | 16 | b |
| Guerdjikova et al. (2008) | escitalopram | 26.5 | 21 (21/0) | 36.9 | placebo | — | 23 (22/1) | 41 | 12 | abcd |
| Leombruni et al. (2008) | sertraline | 165.9 | 22 (22/0) | — | fluoxetine | 64.5 | 20 (20/0) | — | 24 | abd |
| McElroy et al. (2003) | citalopram | 57.9 | 19 (18/1) | 42 | placebo | — | 19 (18/1) | 39.2 | 6 | abcd |
HAMD score, Hamilton Rating Scale for Depression score; *, Take the average; —, Not reported in the literature, but all described as comparable; a, binge frequency; b, the all-cause discontinuation rate; c, HAMD score; d, weight.